Gilead's Irish unit records pre-tax loss of €1.63bn

Revenues declined primarily due to lower Hepatitis C product sales

Gilead last year announced a €7m expansion to its Irish operations with the creation of an additional 140 jobs here.

The main Irish unit of pharmaceutical giant, Gilead last year recorded a pre-tax loss of $1.84bn (€1.63bn).

New accounts show that Cork-based maker, Gilead Sciences Ireland Unlimited (GSIU) which produces drugs to combat HIV and Hepatitis C, last year sustained the pre-tax loss after it recorded a non-cash impairment of $18.4bn in a financial asset.